# Association of serum albumin levels with multidomain functional impairment (motor, balance, ADL, and cognitive impairment) in Chinese post-stroke patients: a multicenter cross-sectional study

**Authors:** Jie Zhu, Ranran Bi, Yansheng Lin, Shuyang Zhang, Yifang Lin, Xuezhen Zhao, Jiali Lin, Jie Jia

PMC · DOI: 10.3389/fneur.2026.1763978 · Frontiers in Neurology · 2026-02-19

## TL;DR

Low serum albumin levels are linked to worse recovery in multiple areas after stroke in Chinese patients.

## Contribution

This study identifies serum albumin as an independent predictor of multidomain functional recovery post-stroke in a Chinese population.

## Key findings

- Higher serum albumin levels correlate with better motor, balance, ADL, and cognitive outcomes.
- A dose-dependent improvement is observed across albumin quartiles.
- The association between albumin and motor function is stronger in females.

## Abstract

Malnutrition, frequently indicated by hypoalbuminemia, is prevalent post-stroke and associated with adverse functional outcomes. However, the independent role of serum albumin (ALB) in multidomain functional recovery—encompassing motor, balance, cognitive, and daily living domains—remains underexplored in Chinese populations. This multicenter study aimed to quantify the independent association between serum ALB levels and functional impairment in Chinese post-stroke patients.

In this cross-sectional study, 1,741 patients from rehabilitation centers across China were enrolled. ALB levels were categorized into quartiles (Q1: <37.7 g/L; Q2: 37.7–40.0 g/L; Q3: 40.0–42.8 g/L; Q4: ≥42.8 g/L). Outcomes included motor function (Fugl-Meyer Assessment), activities of daily living (Modified Barthel Index), balance (Berg Balance Scale), and cognition (Montreal Cognitive Assessment). Multivariable linear regression models adjusted for demographics, comorbidities, lesion characteristics, and illness duration. Subgroup analyses tested interactions by age, sex, BMI, and lesion topography.

Each 1-g/L ALB increase independently predicted functional gains: FMA (β = 1.35, 95% CI: 0.99–1.72), ADL (β = 1.77, 1.44–2.10), BBS (β = 1.02, 0.78–1.26), MoCA (β = 0.30, 0.21–0.40) (all p < 0.001). Dose-dependent improvements were observed across quartiles (Q4 vs. Q1: FMA Δβ = 15.11 [11.09–19.12]; ADL Δβ = 19.35[15.76–22.93]; P trend < 0.001). Sex significantly modified ALB-FMA associations (P interaction = 0.017), with females showing stronger effects (β = 1.81 [1.12–2.51]) than males (β = 1.15 [0.72–1.58]). Cerebellar lesions demonstrated non-significant trend toward amplified associations (FMA: β = 2.16 [0.72–3.59]).

ALB levels are independently and dose-dependently associated with motor, ADL, balance, and cognitive function in post-stroke patients. Compared to lower quartiles, patients with ALB ≥42.8 g/L (highest quartile) exhibit superior functional outcomes. A sex-specific pattern is observed solely in motor function, where the correlation is more pronounced in females. ALB may serve as a biological indicator for risk stratification during stroke rehabilitation.

## Linked entities

- **Diseases:** stroke (MONDO:0005098)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** sarcopenia (MESH:D055948), hepatic or renal impairment (MESH:D008107), inflammation (MESH:D007249), physical (MESH:D059445), muscle catabolism (MESH:D019042), Coronary heart disease (MESH:D003327), DM (MESH:D003920), Ischemic (MESH:D002545), cerebral edema (MESH:D001929), lesions (MESH:D009059), Hemorrhagic (MESH:D006470), protein-energy wasting (MESH:D011502), hypoalbuminemia (MESH:D034141), Stroke (MESH:D020521), pneumonia (MESH:D011014), seizures (MESH:D012640), Cerebellar lesions (MESH:D002526), Post-stroke functional impairment (MESH:D004834), nutritional deficit (MESH:D009748), Hypertension (MESH:D006973), Malnutrition (MESH:D044342), hyper- or hypothyroidism (MESH:D007037), ischemic or hemorrhagic stroke (MESH:D002543), infection (MESH:D007239), functional deficits (MESH:D001289), ischemic stroke (MESH:D002544), rheumatologic disease (MESH:D012216), thyroid dysfunction (MESH:D013959), heart failure (MESH:D006333), deficits in motor control, (MESH:D007174), depressive symptoms (MESH:D003866), CAD (MESH:D003324), diabetic ketoacidosis (MESH:D016883), cognitive decline (MESH:D003072), disability (MESH:D009069)
- **Chemicals:** FMA (MESH:C057525), Alcohol (MESH:D000438)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960116/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960116/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960116/full.md

---
Source: https://tomesphere.com/paper/PMC12960116